NVX-CoV2373 (marketed as Nuvaxovid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine Protein-based vaccines have a long history of use that may make them more acceptable to patients who are hesitant to receive mRNA vaccination. 1 NVX-CoV2373 consists of a recombinant spike protein subunit plus adjuvant. It may also be considered for people who are allergic to components of mRNA vaccines (e.g., polyethylene glycol). 2 2 NVX-CoV2373 can be used in a primary series of vaccination NVX-CoV2373 can be administered in a 2-dose primary series or as a heterologous primary series with another approved vaccine against SARS-CoV-2. Doses should be separated by 8 weeks to maximize immune response. 2 3 NVX-CoV2373 may be offered as a boosterAlthough not approved by Health Canada for this indication, the National Advisory Committee on Immunizations recommends NVX-CoV2373 as a booster 6 months after any primary series. 2
Le NVX-CoV2373 (commercialisé sous le nom Nuvaxovid ) est un vaccin à sous-unités protéiques contre l'infection au SRAS-CoV-2, approuvé au Canada pour les adultes incapables de recevoir un vaccin à ARN messager ou qui ne le souhaitent pas Les vaccins à sous-unités protéiques sont employés depuis de nombreuses d'années, ce qui peut les rendre plus acceptables pour les patients réticents à recevoir un vaccin à ARN messager 1 . Le NVX-CoV2373 est constitué d'une sous-unité de protéine de spicule recombinante couplée à un adjuvant. Il peut aussi être envisagé pour les personnes allergiques à des composants des vaccins à ARN me ssager (p. ex., le glycol polyéthylénique) 2 .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.